Cargando…

Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression

BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesse, Raphael, Lausser, Ludwig, Gummert, Pauline, Schmid, Florian, Wahler, Anke, Schnack, Cathrin, Kroker, Katja S., Otto, Markus, Tumani, Hayrettin, Kestler, Hans A., Rosenbrock, Holger, von Arnim, Christine A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343324/
https://www.ncbi.nlm.nih.gov/pubmed/28274265
http://dx.doi.org/10.1186/s13195-017-0245-y
_version_ 1782513345189904384
author Hesse, Raphael
Lausser, Ludwig
Gummert, Pauline
Schmid, Florian
Wahler, Anke
Schnack, Cathrin
Kroker, Katja S.
Otto, Markus
Tumani, Hayrettin
Kestler, Hans A.
Rosenbrock, Holger
von Arnim, Christine A. F.
author_facet Hesse, Raphael
Lausser, Ludwig
Gummert, Pauline
Schmid, Florian
Wahler, Anke
Schnack, Cathrin
Kroker, Katja S.
Otto, Markus
Tumani, Hayrettin
Kestler, Hans A.
Rosenbrock, Holger
von Arnim, Christine A. F.
author_sort Hesse, Raphael
collection PubMed
description BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential therapeutic targets. Biomarkers that are able to monitor potential treatment effects and that reflect the underlying pathology are of crucial interest. METHODS: In this study, we measured cGMP and cAMP in cerebrospinal fluid (CSF) in a cohort of 133 subjects including 68 AD patients and 65 control subjects. To address the association with disease progression we correlated cognitive status with cyclic nucleotide levels. Because a high burden of NPSs is associated with decrease in cognitive function, we performed an exhaustive evaluation of AD-relevant marker combinations in a depressive subgroup. RESULTS: We show that cGMP, but not cAMP, levels in the CSF of AD patients are significantly reduced compared with the control group. Reduced cGMP levels in AD patients correlate with memory impairment based on Mini-Mental State Examination score (r = 0.17, p = 0.048) and tau as a marker of neurodegeneration (r = –0.28, p = 0.001). Moreover, we were able to show that AD patients suffering from current depression show reduced cGMP levels (p = 0.07) and exhibit a higher degree of cognitive impairment than non-depressed AD patients. CONCLUSION: These results provide further evidence for an involvement of cGMP in AD pathogenesis and accompanying co-morbidities, and may contribute to elucidating synaptic plasticity alterations during disease progression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0245-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5343324
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53433242017-03-10 Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression Hesse, Raphael Lausser, Ludwig Gummert, Pauline Schmid, Florian Wahler, Anke Schnack, Cathrin Kroker, Katja S. Otto, Markus Tumani, Hayrettin Kestler, Hans A. Rosenbrock, Holger von Arnim, Christine A. F. Alzheimers Res Ther Research BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential therapeutic targets. Biomarkers that are able to monitor potential treatment effects and that reflect the underlying pathology are of crucial interest. METHODS: In this study, we measured cGMP and cAMP in cerebrospinal fluid (CSF) in a cohort of 133 subjects including 68 AD patients and 65 control subjects. To address the association with disease progression we correlated cognitive status with cyclic nucleotide levels. Because a high burden of NPSs is associated with decrease in cognitive function, we performed an exhaustive evaluation of AD-relevant marker combinations in a depressive subgroup. RESULTS: We show that cGMP, but not cAMP, levels in the CSF of AD patients are significantly reduced compared with the control group. Reduced cGMP levels in AD patients correlate with memory impairment based on Mini-Mental State Examination score (r = 0.17, p = 0.048) and tau as a marker of neurodegeneration (r = –0.28, p = 0.001). Moreover, we were able to show that AD patients suffering from current depression show reduced cGMP levels (p = 0.07) and exhibit a higher degree of cognitive impairment than non-depressed AD patients. CONCLUSION: These results provide further evidence for an involvement of cGMP in AD pathogenesis and accompanying co-morbidities, and may contribute to elucidating synaptic plasticity alterations during disease progression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0245-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-09 /pmc/articles/PMC5343324/ /pubmed/28274265 http://dx.doi.org/10.1186/s13195-017-0245-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hesse, Raphael
Lausser, Ludwig
Gummert, Pauline
Schmid, Florian
Wahler, Anke
Schnack, Cathrin
Kroker, Katja S.
Otto, Markus
Tumani, Hayrettin
Kestler, Hans A.
Rosenbrock, Holger
von Arnim, Christine A. F.
Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title_full Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title_fullStr Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title_full_unstemmed Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title_short Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
title_sort reduced cgmp levels in csf of ad patients correlate with severity of dementia and current depression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343324/
https://www.ncbi.nlm.nih.gov/pubmed/28274265
http://dx.doi.org/10.1186/s13195-017-0245-y
work_keys_str_mv AT hesseraphael reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT lausserludwig reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT gummertpauline reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT schmidflorian reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT wahleranke reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT schnackcathrin reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT krokerkatjas reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT ottomarkus reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT tumanihayrettin reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT kestlerhansa reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT rosenbrockholger reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression
AT vonarnimchristineaf reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression